A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
Acta Med Okayama
; 74(1): 89-94, 2020 Feb.
Article
em En
| MEDLINE
| ID: mdl-32099255
ABSTRACT
No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma Anaplásico de Células Grandes
/
Transplante de Células-Tronco Hematopoéticas
/
Condicionamento Pré-Transplante
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Child
/
Humans
Idioma:
En
Revista:
Acta Med Okayama
Ano de publicação:
2020
Tipo de documento:
Article